IL292206B2 - The salts of a compound and its crystalline forms - Google Patents

The salts of a compound and its crystalline forms

Info

Publication number
IL292206B2
IL292206B2 IL292206A IL29220622A IL292206B2 IL 292206 B2 IL292206 B2 IL 292206B2 IL 292206 A IL292206 A IL 292206A IL 29220622 A IL29220622 A IL 29220622A IL 292206 B2 IL292206 B2 IL 292206B2
Authority
IL
Israel
Prior art keywords
salts
compound
crystalline forms
crystalline
forms
Prior art date
Application number
IL292206A
Other languages
English (en)
Hebrew (he)
Other versions
IL292206A (en
IL292206B1 (en
Inventor
Wenji Li
Ling Feng
Original Assignee
Hutchmed Ltd
Wenji Li
Ling Feng
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchmed Ltd, Wenji Li, Ling Feng filed Critical Hutchmed Ltd
Publication of IL292206A publication Critical patent/IL292206A/en
Publication of IL292206B1 publication Critical patent/IL292206B1/en
Publication of IL292206B2 publication Critical patent/IL292206B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/185Saturated compounds having only one carboxyl group and containing keto groups
    • C07C59/225Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL292206A 2019-10-14 2020-10-13 The salts of a compound and its crystalline forms IL292206B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910973785 2019-10-14
PCT/CN2020/120594 WO2021073494A1 (en) 2019-10-14 2020-10-13 The salts of a compound and the crystalline forms thereof

Publications (3)

Publication Number Publication Date
IL292206A IL292206A (en) 2022-06-01
IL292206B1 IL292206B1 (en) 2025-11-01
IL292206B2 true IL292206B2 (en) 2026-03-01

Family

ID=75537486

Family Applications (1)

Application Number Title Priority Date Filing Date
IL292206A IL292206B2 (en) 2019-10-14 2020-10-13 The salts of a compound and its crystalline forms

Country Status (14)

Country Link
US (1) US12559472B2 (enExample)
EP (1) EP4045484A4 (enExample)
JP (2) JP2022552329A (enExample)
KR (1) KR20220088712A (enExample)
CN (3) CN114555558B (enExample)
AR (1) AR120202A1 (enExample)
AU (1) AU2020367905A1 (enExample)
BR (1) BR112022007035A2 (enExample)
CA (1) CA3154064A1 (enExample)
IL (1) IL292206B2 (enExample)
MX (1) MX2022004274A (enExample)
TW (1) TWI895290B (enExample)
UA (1) UA129777C2 (enExample)
WO (1) WO2021073494A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022411531B2 (en) * 2021-12-13 2025-01-16 Abbisko Therapeutics Co., Ltd. Fgfr4 inhibitor acid salt, preparation method therefor, and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014139465A1 (en) * 2013-03-15 2014-09-18 Hutchison Medipharma Limited Novel pyrimidine and pyridine compounds and their usage

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
CN107660200B (zh) * 2015-04-14 2022-01-11 卫材R&D管理有限公司 结晶fgfr4抑制剂化合物和其用途
TW201833112A (zh) * 2016-12-01 2018-09-16 大陸商和記黃埔醫藥(上海)有限公司 化合物的晶型

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014139465A1 (en) * 2013-03-15 2014-09-18 Hutchison Medipharma Limited Novel pyrimidine and pyridine compounds and their usage

Also Published As

Publication number Publication date
JP2025143319A (ja) 2025-10-01
CN119462616A (zh) 2025-02-18
CN114555558B (zh) 2024-12-17
IL292206A (en) 2022-06-01
BR112022007035A2 (pt) 2022-06-28
US12559472B2 (en) 2026-02-24
WO2021073494A1 (en) 2021-04-22
EP4045484A4 (en) 2023-09-06
AR120202A1 (es) 2022-02-02
CA3154064A1 (en) 2021-04-22
KR20220088712A (ko) 2022-06-28
TWI895290B (zh) 2025-09-01
AU2020367905A1 (en) 2022-04-21
JP2022552329A (ja) 2022-12-15
CN114555558A (zh) 2022-05-27
US20230121346A1 (en) 2023-04-20
TW202128669A (zh) 2021-08-01
UA129777C2 (uk) 2025-07-30
IL292206B1 (en) 2025-11-01
EP4045484A1 (en) 2022-08-24
CN119751422A (zh) 2025-04-04
MX2022004274A (es) 2022-05-06

Similar Documents

Publication Publication Date Title
IL270872A (en) Crystalline forms of an FGFR inhibitor and a process for their preparation
IL279195A (en) New salts and crystals
IL282996A (en) Crystalline forms of a modified imidazopyridine compound and their use as P2X3 modulators
SI3894012T1 (sl) Kristalinične oblike in oblike soli kinaznega inhibitorja
IL289929A (en) Crystal forms of cd73 inhibitor
IL289453A (en) Process for the preparation of ridinilazole and crystalline forms thereof
IL288348A (en) Synthesis method of furoimidazopyridine compound, crystal form of furoimidazopyridine compound, and crystal form of salt thereof
IL288484A (en) Crystalline salt forms of a kinase inhibitor
CA3275666A1 (en) Crystalline forms of the nrtti compound 4’-ethynyl-2-fluoro-2’- deoxyadenosine
GB202102360D0 (en) Crystalline compound
IL281168A (en) Crystal forms of the quinazole compound and its hydrochloride salts
ZA202200964B (en) Salts of a compound, crystal forms of the salts and preparation method and use thereof
IL272835A (en) Salts of a compound and crystalline forms thereof
SG11202103804TA (en) Crystalline salts of a plasma kallikrein inhibitor
ZA202107474B (en) Sulcardine salts
CA189106S (en) Fastener
IL293806B1 (en) Production of protected DO3A salts
ZA202007034B (en) The crystalline forms of a compound
IL292206A (en) The salts of a compound and its crystalline forms
EP3927707A4 (en) SOLID POLYMORPHS OF AN FLNA BINDING COMPOUND AND ITS HYDROCHLORIDE SALTS
IL292847A (en) Crystalline forms of magl inhibitor
IL279953A (en) Crystal forms of LTA4H inhibitor
SG11202105355XA (en) Crystalline salts of corydalmine
GB201912411D0 (en) Crystalline forms of ivosidenib
SG11202009262VA (en) Salts of compounds and crystals thereof